Abstract
Chimeric antigen receptor T (CAR-T) cell therapy achieved extraordinary achievements results in antitumor treatments, especially against hematological malignancies, where it leads to remarkable, long-term antineoplastic effects with higher target specificity. Nevertheless, some limitations persist in autologous CAR-T cell therapy, such as high costs, long manufacturing periods, and restricted cell sources. The development of a universal CAR-T (UCAR-T) cell therapy is an attractive breakthrough point that may overcome most of these drawbacks. Here, we review the progress and challenges in CAR-T cell therapy, especially focusing on comprehensive comparison in UCAR-T cell therapy to original CAR-T cell therapy. Furthermore, we summarize the developments and concerns about the safety and efficiency of UCAR-T cell therapy. Finally, we address other immune cells, which might be promising candidates as a complement for UCAR-T cells. Through a detailed overview, we describe the current landscape and explore the prospect of UCAR-T cell therapy.
Introduction: The Limitations of Autologous CAR-T
While autologous CAR-T cell therapy has revolutionized the treatment of blood cancers, it faces three major "plights" that hinder widespread adoption. First is the high cost and complexity; custom-manufacturing a batch for every single patient can cost upwards of $475,000. Second is the time lag, as the 2–4 week production cycle is often too slow for patients with rapidly progressing malignancies. Finally, cell quality is a concern, as patients who have undergone heavy chemotherapy often have "exhausted" T cells that are difficult to engineer, or their samples may be contaminated with malignant cells.
Universal CAR-T (UCAR-T) aims to solve these issues by using healthy donor cells to create standardized, "off-the-shelf" batches that are ready for immediate use.
Engineering the "Off-the-Shelf" Solution
The transition from patient-specific to universal therapies requires sophisticated engineering to prevent graft-versus-host disease (GVHD) and host rejection.
Gene Editing Strategies
The core of UCAR-T lies in advanced gene editing. Technologies like CRISPR/Cas9, TALENs, and ZFNs are employed to knock out the T-cell receptor (TCR) to prevent GVHD and the MHC/HLA molecules to prevent the patient's immune system from rejecting the donor cells. Additionally, immune checkpoints like PD-1 or CTLA-4 can be edited to enhance potency.
Modular and Switchable CAR Designs
Beyond simple knockouts, researchers are developing modular "split" CAR systems (e.g., SUPRA CAR). In these designs, the signaling module on the T cell is separate from the antigen-recognition "switching" module. This allows for fine-tuned control over T-cell activity via external adapters and enables the use of logic gating (AND, OR, and NOT gates) to improve specificity and reduce "on-target, off-tumor" toxicity.
Key Insights and Clinical Progress
The TCR/CAR Competition
A critical insight is the "delicate relationship" between the native TCR and the engineered CAR. If both are active, the cell can suffer from "double stimulation," leading to rapid exhaustion. Knocking out the TCR isn't just a safety measure against GVHD; it may actually improve the functional lifespan of the CAR-T cell by reducing this competition.
Clinical Efficacy and the Role of Lymphodepletion
Clinical data from landmark trials like UCART19 (NCT02735083, NCT02808442) has provided proof-of-concept for the universal approach. In these trials for B-cell acute lymphoblastic leukemia, 67% (14/21) of patients achieved a complete response. A key finding is that UCAR-T cells only expand effectively if the patient undergoes intensive "pre-conditioning" (lymphodepletion) to temporarily suppress their own immune system, creating a "window" for the donor cells to work. While Cytokine Release Syndrome (CRS) occurred in 91% of patients, it was mostly manageable, and acute skin GVHD was rare (10%), validating the gene-editing approach.
Future Frontiers
Despite significant progress and a 46.7% increase in anticancer cell therapies under research between 2019 and 2020, hurdles remain:
- Persistence: UCAR-T cells often don't last as long as autologous ones because the patient’s immune system eventually clears the foreign donor cells.
- Solid Tumors: Success is currently limited to "liquid" blood cancers. Overcoming the physical barriers and immunosuppressive microenvironment of solid tumors is the next major frontier.
- Alternative Cell Sources: Naturally universal cells like NK cells, γδ T cells, and iNKT cells are being explored as they lack the TCR that causes GVHD. Additionally, induced Pluripotent Stem Cells (iPSCs) could provide an infinite supply of genetically identical "perfect" CAR-T cells, though concerns about tumorigenicity must be addressed.
Summary updated